Smoking is the main cause of bladder cancer, responsible for roughly half of all diagnosed cases. When you smoke, carcinogenic chemicals from tobacco are absorbed into your bloodstream, filtered by your kidneys, and concentrated in your urine, where they sit in direct contact with the bladder lining for up to 18 hours. That prolonged exposure damages the cells lining the bladder and, over time, can trigger the mutations that lead to cancer.
Bladder cancer is common. An estimated 84,530 new cases will be diagnosed in the United States in 2026, and men are about four times more likely to develop it than women, with a diagnosis rate of 31 per 100,000 males compared to 7.6 per 100,000 females. While smoking dominates the risk landscape, several other factors can also cause or contribute to the disease.
Why Smoking Is the Leading Cause
Tobacco smoke contains dozens of known carcinogens. After you inhale, your body processes these chemicals and excretes them through your kidneys. The bladder, which stores urine before you urinate, becomes a holding tank for these toxins. Unlike the lungs, where exposure to smoke is brief with each breath, the bladder lining can be bathed in carcinogen-laced urine for hours at a stretch.
This matters because frequency and duration of exposure are what turn a dangerous chemical into an actual cancer. Someone who smokes a pack a day for 20 years gives their bladder lining tens of thousands of hours of contact with cancer-causing compounds. The risk doesn’t vanish immediately after quitting, but it does decline steadily over the years that follow. Former smokers still carry a higher risk than people who never smoked, but a significantly lower risk than current smokers.
Workplace Chemical Exposure
Occupational exposure to a class of industrial chemicals called aromatic amines is the second most established cause of bladder cancer. Workers in chemical manufacturing, dye production, rubber processing, and leather tanning have historically faced the highest risk. Specific compounds linked to bladder cancer include o-toluidine, aniline, and 4-aminobiphenyl.
The connection is well documented. A study of workers at a chemical manufacturing plant found that employees who never worked in the department using these compounds had no increased cancer risk compared to the general population. Those who worked directly with the chemicals had more than six times the expected rate of bladder cancer. Modern workplace regulations have reduced exposure levels, but the cancers that result from these chemicals can take 20 to 30 years to appear, so cases linked to past exposure still surface today.
Arsenic in Drinking Water
Arsenic is an established cause of bladder cancer. Populations drinking water with high arsenic concentrations have clearly elevated rates of the disease, and emerging evidence suggests that even low to moderate levels of exposure may increase risk. The U.S. Environmental Protection Agency sets 10 micrograms per liter as the safety standard for public water supplies, but private wells are not subject to this regulation and can contain higher levels.
If you rely on a private well, testing your water for arsenic is a straightforward step. State and county health departments typically offer testing resources, and filtration systems designed to remove arsenic are widely available.
Chronic Infection and Inflammation
Long-term irritation of the bladder lining is another pathway to cancer. The clearest example is infection with a parasitic worm called Schistosoma haematobium, which is common in parts of Africa and the Middle East. The parasite deposits eggs in the bladder wall, causing chronic inflammation that drives repeated cycles of tissue damage and repair. Over years, this can lead to a type of bladder cancer called squamous cell carcinoma, which is distinct from the more common type seen in Western countries.
The mechanism involves more than just physical irritation. Inflammatory cells release oxygen radicals that can directly damage DNA. Bacteria that thrive in the inflamed, infected bladder also produce compounds called N-nitrosamines, which are carcinogenic on their own. This combination of mechanical damage, DNA-harming free radicals, and bacterial carcinogens creates a potent cancer-promoting environment. Chronic urinary tract infections and long-term catheter use can set up a similar cycle of inflammation, though the risk is lower than with parasitic infection.
Previous Cancer Treatments
Certain medical treatments for other cancers can raise your bladder cancer risk years later. One well-known culprit is cyclophosphamide, a chemotherapy drug used for blood cancers and some solid tumors. Its breakdown products irritate the bladder lining and can cause a condition called hemorrhagic cystitis, and long-term use is associated with secondary bladder malignancies.
Radiation therapy directed at the pelvic area, commonly used for cervical, prostate, or colorectal cancers, also increases risk. Patients treated with both chemotherapy and radiation together tend to have the highest rates of secondary cancers. These treatment-related bladder cancers typically appear years or even decades after the original therapy, which is why long-term follow-up matters for cancer survivors.
Two Genetic Pathways
Not all bladder cancers behave the same way, and researchers have identified two largely separate genetic tracks that explain why. Mutations in a gene called FGFR3 are found in about 71% of early, superficial bladder tumors and are associated with low-grade, slower-growing disease. Mutations in the tumor suppressor gene TP53, on the other hand, appear in 47% of tumors that have invaded the muscle wall and are linked to high-grade, aggressive cancers.
These two mutation types are almost mutually exclusive, meaning a tumor typically follows one path or the other. This distinction has practical implications: low-grade tumors driven by FGFR3 mutations tend to recur but rarely become life-threatening, while TP53-driven tumors are more likely to spread and require aggressive treatment. Understanding which pathway a tumor follows helps guide treatment decisions.
Early Warning Signs
The most common first sign of bladder cancer is blood in your urine. It may turn your urine bright red or cola-colored, or it may be invisible to the naked eye and only detected on a routine lab test. Other early symptoms include urinating more frequently than usual, pain during urination, and back pain. These symptoms overlap with far more common conditions like urinary tract infections, which is why bladder cancer can go undiagnosed for months.
Blood in your urine that appears even once and then goes away is still worth investigating. Bladder cancer often causes intermittent bleeding, so the absence of blood on a follow-up urine test doesn’t rule it out.
Survival by Stage
When bladder cancer is caught early, outcomes are favorable. The five-year relative survival rate for the earliest stage, where abnormal cells are confined to the bladder’s inner lining, is 97%. For localized cancer that hasn’t spread beyond the bladder wall, the rate is 71%. Once the disease reaches nearby lymph nodes or organs, survival drops to 39%, and for cancer that has spread to distant parts of the body, it falls to 8%.
These numbers underscore why paying attention to early symptoms matters, particularly if you smoke or have a history of occupational chemical exposure. Most bladder cancers are diagnosed at an early, treatable stage, and that early detection is the single biggest factor in long-term survival.